Sonoma Pharmaceuticals Ownership
| SNOA Stock | USD 0.16 0.01 6.67% |
Shares in Circulation | First Issued 2004-06-30 | Previous Quarter 5.2 M | Current Value 10.9 M | Avarage Shares Outstanding 907.4 K | Quarterly Volatility 1.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sonoma |
Sonoma Stock Ownership Analysis
The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonoma Pharmaceuticals recorded a loss per share of 0.82. The entity last dividend was issued on the 20th of June 2019. The firm had 1:9 split on the 20th of June 2019. Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia. Sonoma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about Sonoma Pharmaceuticals contact James Schutz at 800 759 9305 or learn more at https://www.sonomapharma.com.Besides selling stocks to institutional investors, Sonoma Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sonoma Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sonoma Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sonoma Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Only 1.55% of Sonoma Pharmaceuticals are currently held by insiders. Unlike Sonoma Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sonoma Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sonoma Pharmaceuticals' insider trades
Sonoma Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonoma Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonoma Pharmaceuticals backward and forwards among themselves. Sonoma Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Sonoma Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2023-12-31 | 105 | Morgan Stanley - Brokerage Accounts | 2023-01-31 | 86.0 | Hanson Mcclain Inc | 2023-12-31 | 65.0 | Bank Of America Corp | 2023-12-31 | 44.0 | Hbc Financial Services, Pllc | 2023-12-31 | 2.0 | Newsquare Capital, Llc | 2023-09-30 | 0.0 | Renaissance Technologies Corp | 2023-12-31 | 0.0 | Gradient Investments | 2023-09-30 | 0.0 | Virtu Financial Llc | 2023-09-30 | 0.0 | Geode Capital Management, Llc | 2023-12-31 | 35.8 K | Jpmorgan Chase & Co | 2023-12-31 | 33 K |
Sonoma Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonoma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonoma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonoma Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bruce Thornton over three months ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over six months ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Currently Active Assets on Macroaxis
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Sonoma Stock analysis
When running Sonoma Pharmaceuticals' price analysis, check to measure Sonoma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sonoma Pharmaceuticals is operating at the current time. Most of Sonoma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Sonoma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sonoma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Sonoma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Sonoma Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.82) | Revenue Per Share 1.946 | Quarterly Revenue Growth 0.066 | Return On Assets (0.19) | Return On Equity (0.83) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.